Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Galapagos NV

Market Cap 1.65B 1.92B 1.52B 1.43B 2.68B 181B 2.71B 17.98B 7.02B 88.74B 7.2B 7.04B 307B P/E Ratio 2026 *
-10.9x
P/E Ratio 2027 * -10x
Enterprise Value -1.15B -1.33B -1.06B -993M -1.87B -126B -1.88B -12.51B -4.89B -61.75B -5.01B -4.9B -214B EV / Sales 2026 *
-6.35x
EV / Sales 2027 * -4.88x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 64 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 13/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.92B
+1.41%+1.23%-11.57%-11.66% 43.58B
+4.02%+7.79%+294.33%+536.67% 34.03B
-1.69%-2.89%+13.70%-17.71% 29.77B
+1.41%-0.96%-0.53%+33.41% 29.82B
+1.16%+9.79%+14.27%+22.28% 25.42B
+2.40%+8.49% - - 13.87B
+0.03%+2.10%+56.75%+111.91% 13.35B
+0.60%-1.88%+4.11%+3.67% 12.85B
+0.93%+0.57%+107.81%+77.40% 12.22B
Average +1.03%+1.88%+59.86%+94.50% 23.88B
Weighted average by Cap. +1.26%+1.86%+61.65%+105.83%

Financials

2026 *2027 *
Net sales 181M 210M 167M 156M 294M 19.86B 297M 1.97B 770M 9.72B 788M 772M 33.65B 177M 206M 163M 153M 288M 19.45B 291M 1.93B 754M 9.52B 772M 756M 32.96B
Net income -236M -273M -217M -204M -382M -25.85B -386M -2.56B -1B -12.66B -1.03B -1B -43.8B -144M -167M -133M -125M -234M -15.82B -236M -1.57B -613M -7.75B -628M -615M -26.81B
Net Debt -2.8B -3.25B -2.58B -2.42B -4.55B -307B -4.59B -30.49B -11.91B -150B -12.2B -11.94B -521B -2.52B -2.92B -2.32B -2.17B -4.08B -276B -4.13B -27.4B -10.7B -135B -10.97B -10.73B -468B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!